Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Regulation01:25

Drug Regulation

3.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.2K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

503
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
503
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.2K
Criteria for Causality: Bradford Hill Criteria - II01:28

Criteria for Causality: Bradford Hill Criteria - II

1.4K
The Bradford Hill criteria serve as guidelines for establishing causative links in epidemiological research. Beyond Strength, Consistency, Specificity, and Temporality, key criteria also include Biological Gradient, Plausibility, Coherence, Experiment, and Analogy. These principles assist scientists in assessing the likelihood of causation in complex biological contexts. Below is a summary of these concepts:
1.4K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.2K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.2K
Pharmacovigilance01:19

Pharmacovigilance

1.9K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exogenous salicylic acid promotes the accumulation of volatile sulfur compounds and anti-muscle atrophy activity in garlic sprouts.

Journal of the science of food and agriculture·2026
Same author

Data-adaptive identification of effect modifiers through stochastic shift interventions and cross-validated targeted learning.

Biostatistics (Oxford, England)·2026
Same author

Sphingosine-1-phosphate receptor 1 signaling stimulates human pluripotent stem cell-derived cardiomyocyte differentiation and maturation.

Experimental & molecular medicine·2026
Same author

Estimated Daily Phytosterol Intake from Commonly Consumed Foods in Korea and a Global Comparison.

Journal of nutritional science and vitaminology·2026
Same author

Evaluating the robustness and readiness of large frontier models in health AI applications.

Nature medicine·2026
Same author

Development of a LC-MS-based simultaneous protein quantification method for all regulated allergenic foods in Korea.

Food chemistry·2026

Related Experiment Video

Updated: Mar 1, 2026

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
05:47

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems

Published on: June 13, 2025

1.7K

Methodological and regulatory considerations for causal AI in drug development.

Hana Lee1, Sky Qiu2, Spencer Haupert3

  • 1Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA. hana.lee@fda.hhs.gov.

NPJ Digital Medicine
|February 27, 2026
PubMed
Summary

Artificial intelligence (AI) can improve drug development, but its use in causal inference for treatment effects is limited. This paper explores AI

Related Experiment Videos

Last Updated: Mar 1, 2026

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
05:47

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems

Published on: June 13, 2025

1.7K

Area of Science:

  • Drug development and regulatory science
  • Causal inference methodologies
  • Artificial intelligence applications

Background:

  • Artificial intelligence (AI) presents significant opportunities for advancing drug development processes.
  • Regulatory agencies are increasingly issuing guidance on AI adoption in pharmaceuticals.
  • The application of AI to causal inference, crucial for understanding treatment effects and informing regulatory decisions, remains underdeveloped.

Purpose of the Study:

  • To review current regulatory activities concerning AI in drug development.
  • To examine statistical methodologies for AI-driven causal inference.
  • To identify key regulatory challenges and demonstrate AI's value in causal inference across various data sources and study designs.

Main Methods:

  • Review of regulatory agency documents and guidance on AI.
  • Examination of statistical and machine learning techniques for causal inference.
  • Case illustrations of AI application in diverse drug development data and studies.

Main Results:

  • Limited current regulatory guidance specifically addresses AI for causal inference in drug development.
  • Various AI methodologies show potential for enhancing causal inference from complex datasets.
  • AI can add significant value by integrating diverse data sources to strengthen treatment effect estimation.

Conclusions:

  • There is a need for clearer regulatory pathways for AI-driven causal inference in drug development.
  • Further research and validation of AI statistical methods are required for regulatory acceptance.
  • AI holds substantial promise for improving the accuracy and efficiency of causal inference in pharmaceutical research and regulatory decision-making.